Clinical Trial: A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07656727) titled 'A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors' on June 15.

Brief Summary: The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.

Study Start Date: June 11

Study Type: INTERVENTIONAL

Condition: Obesity and Cardiovascular Risk

Intervent...